ADCE-T02, a potential best-in-class Tissue Factor targeted antibody-drug conjugate (ADC), enters cohort expansion portion of the Tiffany-01 study in advanced solid tumors Two ADCE-T02 publications highlighting important preclinical results at the 2026 AACR Annual Meeting ADCE-D01, a first-in-class uPARAP targeted ADC, granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) First patient dosed in Phase I trial of ADCE-B05, an ADC directed against an undisclosed first-in-cla

April 21, 2026 -- Ionetix Corporation ("Ionetix"), a leading particle accelerator company focused on the medical, materials testing and nuclear energy space announced today it raised more than $30 million in a private placement offering at $3.00 per share. In addition, the company completed a go-public reverse merger transaction with JDEV Acquisition Corp., which has been renamed Ionetix Corp. Ionetix's patent-protected superconducting cyclotron technology supports unique particle accelerator s

Submission based on statistically significant event-free and overall survival data from the Phase 3 EV-304 trial Building on the existing indication in cisplatin-ineligible muscle-invasive bladder cancer (MIBC), if approved, this regimen would be the first and only perioperative treatment for patients with MIBC regardless of cisplatin eligibility, marking a potential new standard of care April 20, 2026 -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer

April 20, 2026 -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has completed its acquisition of CathWorks, a privately held medical device company, which aims to transform how coronary artery disease (CAD) is diagnosed and treated. The acquisition follows a 2022 strategic partnership with a co-promotion agreement for the CathWorks FFRangio® System where it is commercially available in the U.S., Europe and Japan. The acquisition is valued at $585 million

With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights under one owner Advancing felzartamab – a CD38-directed antibody with potential broad applicability across a range of immune-mediated conditions – in the Greater China Region presents an important opportunity in a key global market Agreement builds on TJ Biopharma's development success of felzartamab in China and productive clinical collaboration in Biog

April 20, 2026 -- Immunofoco today announced the presentation of new preclinical data for its in vivo BCMA-targeting CAR-T candidate, IMV102, at the AACR Annual Meeting 2026. The data demonstrate that IMV102 achieved potent and durable anti-tumor activity in multiple myeloma models, highlighting its potential to address key limitations of conventional CAR-T therapies. Autologous CAR-T therapy has achieved remarkable success in hematologic malignancies, yet its widespread use remains challenging

Novo Nordisk said Monday that its sickle cell disease pill succeeded in a late-stage study. However, the data came in behind expectations the company set last year. Etavopivat cut the occurrence of the painful sickle cell complications known as vaso-occlusive crises (VOCs) by 27% compared with placebo, hitting one of the trial’s co-primary endpoints. However, the company’s then-head of rare disease Ludovic Helfgott told Endpoints News last year that Novo was hoping to see a 50% cut. Nonetheles

New data demonstrate the IL-22 AND-Body™ therapeutic, AMP-220, selectively targets gut tissue, conferring improved therapeutic efficacy and tolerability in vivo IND-enabling studies for AMP-220 are ongoing April 20, 2026 -- Ampersand Biomedicines, a Flagship Pioneering multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today announced new preclinical data for AMP-220, a gut-targeted IL-22 AND-Body™ therapeutic. The data wer

ZEPZELCA® (lurbinectedin), in combination with atezolizumab (Tecentriq®), is approved for use in Australia and Singapore as a first-line maintenance treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) [1],[2] SCLC is an aggressive form of lung cancer, accounting for 10-15% of all lung cancer diagnoses [3]-[6] Lung cancer is the leading cause of cancer death in Australia and among men in Singapore, and the second highest among Singaporean women [7]-[9] April 20, 20

The acquisition of Neurona will put UCB in both the epilepsy and cell therapy space, even as many of its fellow pharmas move away from the latter modality. UCB is fronting $650 million to absorb California-based Neurona Therapeutics to deepen its epilepsy portfolio and expand into regenerative medicine. As part of the acquisition agreement, announced Friday afternoon, UCB will also put up to $500 million on the line in milestone payments. The companies expect to consummate the transaction by t